BTK and B-cell chronic lymphocytic leukemia: The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib has been a major advance for chronic lymphocytic leukemia (CLL) patients but it does not cure as a single agent, outcomes for patients who ultimately progress on it are poor, and strategies to improve its activity are needed.1, 2